Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
02/2003
02/05/2003EP1280904A2 Pain signaling molecules
02/05/2003EP1280899A2 Gene and sequence variation associated with sensing carbohydrate compounds and other sweeteners
02/05/2003EP1280820A2 Anti-inflammatory compounds and uses thereof
02/05/2003EP1280816A1 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them
02/05/2003EP1280806A1 THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
02/05/2003EP1280805A1 Novel imidazotriazinones and the use thereof
02/05/2003EP1280803A1 Crystalline form ii of cabergoline
02/05/2003EP1280799A1 Ortho-substituted anthranilic acid amides and their use as medicaments
02/05/2003EP1280793A2 Cyclic amidine compounds and their use as alpha4beta2 nicotinic acetylcholine receptor ligands
02/05/2003EP1280785A1 Phenylsulphonylpiperazinyl derivatives as 5-ht receptor ligands
02/05/2003EP1280781A1 5-ht 7 receptor antagonists
02/05/2003EP1280779A1 New polycyclic indanylimidazoles with alpha2 adrenergic activity
02/05/2003EP1280777A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
02/05/2003EP1280776A1 Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
02/05/2003EP1280774A1 Substituted indoles as parp inhibitors
02/05/2003EP1280760A1 Novel spiro[2.4]heptane amino carboxy compounds and derivatives thereof
02/05/2003EP1280554A2 A pharmaceutical composition and method of treatment of diseases of cognitive dysfuntion in a mammal
02/05/2003EP1280546A1 Method and composition for the treatment of angiogenesis
02/05/2003EP1280536A2 Method for treating retinal degeneration with purinergic receptor agonists
02/05/2003EP1280533A2 Aldosterone antagonist composition for release during aldosterone acrophase
02/05/2003EP1280529A2 Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
02/05/2003EP1280528A2 R-eliprodil for treating glaucoma
02/05/2003EP1280525A2 Methods and compositions for modulating alpha adrenergic receptor activity
02/05/2003EP1280524A2 Methods and compositions for modulating alpha adrenergic receptor activity
02/05/2003EP1280515A2 Pharmaceutical compositions comprising cannabis
02/05/2003EP1280486A1 Minimizing adverse experience associated with oxybutynin therapy
02/05/2003EP1280485A1 Improved transdermal drug patch
02/05/2003EP1014960B1 Use of a specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
02/05/2003EP1003486B1 Pharmaceutical compositions containing an effervescent acid-base couple
02/05/2003EP0848706B1 Substituted benzene-fused heterocyclics as neurokinin antagonists
02/05/2003EP0819760B1 Process for producing phosphatidylserines having polybasic unsaturated fatty acid as side chain
02/05/2003CN1395581A Recombinant antibodies to human IL-1 beta
02/05/2003CN1395575A Novel piperidine compounds and drugs containing the same
02/05/2003CN1395573A Extraction of flavonoids
02/05/2003CN1395568A 1,2-diaryl benzimidazole derivative for treating illnesses associated with microglia activation
02/05/2003CN1395567A New imidazole derivatives
02/05/2003CN1395566A Corticotropin releasing factor antagonists
02/05/2003CN1395563A Isatine derivatives with neurotrophic activity
02/05/2003CN1395558A Substituted benzoylguanidines, method for their production, their use as medicament or diagnostic agent and mediciment containing same
02/05/2003CN1395556A Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl] cyclohexanecarboxylate
02/05/2003CN1395488A Drospirenone for hormone replacement therapy
02/05/2003CN1395487A The use of mirtazapine for treatment of sleep disorders
02/05/2003CN1395486A Drug combination for treatment of depression and related disorders comprising mirtazapine and gepirone
02/05/2003CN1394962A Method for producing human brain-derived neurotrophic factor NDNF by using methanol yeast (pichia pastoris) and its application
02/05/2003CN1394960A Method for producing neurotrophon-3 (NT-3) by using methanol yeast (pichia pastoris) and its application
02/05/2003CN1394855A Substituted heterocyclic compound
02/05/2003CN1394632A Health-care food for improving sleep
02/05/2003CN1394612A Antler gelatin medicated liquor for curing sciatica and its preparation method
02/05/2003CN1394605A Nimodipine oral disintegrant tablet for curing dementia and its preparation method
02/05/2003CN1394597A Process for preparing powder preparation
02/05/2003CN1100785C 1,3,4,5-tetrahydrobenzo [c] azepin-3-one disulfide derivative and method
02/05/2003CN1100779C 3-aryl substituted pyrazolo [4,3-d] pyriidine derivatives, corticotropin-releasing factor receptor (CRF1) specific ligands
02/05/2003CN1100777C N-heterocyclic derivatives as NOS inhibitor
02/05/2003CN1100748C Inhibition of matrix metalloproteases by 2-substituted-4-(4-substituted phenyl)-4-oxobutyric acids
02/05/2003CN1100557C External-use Chinese medicine preparation for curing cerebrovascular disease
02/05/2003CN1100548C Chinese medicine composition for treating intractable headache
02/05/2003CN1100541C Therapeutic uses and delivery systems of dehydroepiandrosterone
02/05/2003CN1100533C Melatonin derivatives for usein terating desynchronization disorders
02/04/2003US6515197 Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide
02/04/2003US6515173 Inhibitors of the ICE/ced-3 family of cysteine proteases
02/04/2003US6515117 C-aryl glucoside SGLT2 inhibitors and method
02/04/2003US6515103 Polypeptides naturally occurring in venom of cone snails; include gamma-carboxyglutamic acid; use as anticonvulsant, neuroprotective, and pain management agents
02/04/2003US6515020 Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders
02/04/2003US6515019 Methods of providing symptomatic and prophylactic treatment for medical and neurological conditions
02/04/2003US6515016 Treating or preventing multiple sclerosis, by administering an antimicrotubule agent; treating various other inflammatory diseases
02/04/2003US6515005 Substituted azole derivatives as inhibitors of corticotropin releasing factor
02/04/2003US6515002 Compounds and compositions for treating C1s-mediated diseases and conditions
02/04/2003US6514999 A substance which increases Dopamine concentration in the synaptic cleft of the neurons of the brain, in combination with an effective amount of a local anesthetic of the anilide group or derivatives thereof
02/04/2003US6514993 Serotonin 5-HT1A and dopamin D2 receptor ligands
02/04/2003US6514989 Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
02/04/2003US6514984 Human non-pancreatic secretory phospholipase A2 inhibitors
02/04/2003US6514983 Inhibitors of the nucleic enzyme poly(adenosine 5'-diphospho-ribose)polymerase
02/04/2003US6514982 CRF receptor antagonists and methods relating thereto
02/04/2003US6514976 Arylpiperazines having activity at the serotonin 1A receptor
02/04/2003US6514973 Treatment of transmethylation disorders comprising one or more compounds selected from phosphatidyl serines, methyl transporters, and methyl and methylene donors with exipient
02/04/2003US6514970 Urotensin-II receptor antagonists
02/04/2003US6514969 β-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions
02/04/2003US6514968 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising
02/04/2003US6514961 Such as anxiety and all forms of epilepsy, particularly in humans
02/04/2003US6514960 Use of bismuth subgallate in inhibition of production of nitric oxide synthase
02/04/2003US6514934 For treating sexual dysfunctions in males and females
02/04/2003US6514761 Methods of using BCL-2 for the therapeutic treatment and prevention of diseases
02/04/2003US6514745 Oncoprotein protein kinase
02/04/2003US6514729 Recombinant interferon-beta muteins
02/04/2003US6514686 Alzheimer's disease
02/04/2003US6514531 Controlled-release dosage forms comprising zolpidem or a salt thereof
02/04/2003US6514516 Local anesthetic and a biocompatible controlled release material consisting of polyanhydrides, copolymers of lactic acid and glycolic acid, poly(lactic) acid, poly(glycolic) acid, polyesters, polyorthoesters, proteins, polysaccharides
02/04/2003US6514491 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
02/04/2003CA2272927C Dimesylate salts of neuropeptide y ligands
02/04/2003CA2271566C Substituted phenyl pyrimidines useful in the treatment of cns disorders
02/04/2003CA2268967C Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
01/2003
01/30/2003WO2003008635A2 η-SECRETASE IN VITRO SCREENING ASSAY
01/30/2003WO2003008574A1 Mutations in ion channels
01/30/2003WO2003008566A1 Production of radial glial cells
01/30/2003WO2003008559A2 Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
01/30/2003WO2003008457A2 Polysaccharidic esters of retinoic acid
01/30/2003WO2003008452A2 Bispecific monoclonal antibodies to il-12 and il-18 receptors
01/30/2003WO2003008448A2 Novel human proton-gated channels
01/30/2003WO2003008446A1 Polypeptides relating to signal transfer of advanced glycation end product receptor
01/30/2003WO2003008420A1 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]naphthalenyl derivatives with antipsychotic activity